JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias
K Ono, Y Iwasaki, M Akao, T Ikeda, K Ishii… - Circulation …, 2022 - jstage.jst.go.jp
The Japanese Circulation Society (JCS) published the “Guidelines for Pharmacological
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …
Treatment of Arrhythmia” in 2004, and a revised edition was published in 2009. 1 Both …
Effect of non‐recommended doses versus recommended doses of direct oral anticoagulants in atrial fibrillation patients: A meta‐analysis
X Liu, M Huang, C Ye, X Xiao, C Yan - Clinical Cardiology, 2021 - Wiley Online Library
Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …
Off-label underdosing or overdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis
X Wu, L Hu, J Liu, Q Gu - Frontiers in Cardiovascular Medicine, 2021 - frontiersin.org
Background: Several studies have investigated the role of off-label non-vitamin K antagonist
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
Idarucizumab for emergency reversal of the anticoagulant effects of dabigatran: final results of a Japanese Postmarketing surveillance study
M Yasaka, H Yokota, M Suzuki, H Asakura… - Cardiology and …, 2023 - Springer
Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the
anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which …
anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which …
[HTML][HTML] Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a sub-analysis of the …
H Inoue, M Umeyama, T Yamada, H Hashimoto… - Journal of …, 2020 - Elsevier
Background The safety and effectiveness of reduced-dose apixaban 2.5 mg twice daily (BID)
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …
have not been elucidated thoroughly in Japanese patients with nonvalvular atrial fibrillation …
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: a regulatory postmarketing surveillance, the …
H Inoue, M Umeyama, T Yamada… - Journal of …, 2019 - Wiley Online Library
Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial …
Off‐label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta‐analysis of observational studies
Background Although several meta‐analyses have examined the effects of off‐label
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …
Efficacy and safety of non-recommended dose of new oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis
X Kong, Y Zhu, L Pu, S Meng, L Zhao… - Frontiers in …, 2021 - frontiersin.org
Introduction: The real-world treatment of atrial fibrillation (AF) often involves the prescription
of new oral anticoagulants (NOACs) using dosing both lower and higher than recommended …
of new oral anticoagulants (NOACs) using dosing both lower and higher than recommended …
Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese post-marketing surveillance study
M Yasaka, H Yokota, M Suzuki, H Asakura… - Cardiology and …, 2020 - Springer
Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all …
anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all …
Non-vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies
In the present study, we aimed to provide evidence from high-quality real world studies for a
comprehensive and rigorous analysis on the gastrointestinal bleeding (GIB) risk for non …
comprehensive and rigorous analysis on the gastrointestinal bleeding (GIB) risk for non …